Press Releases BioArctic AB

Equities

BIOA B

SE0010323311

Market Closed - Nasdaq Stockholm Other stock markets 11:29:53 2024-05-06 am EDT			5-day change	1st Jan Change
193.4 ^SEK	-0.10%		-2.61%	-27.63%

Apr. 22	Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest	DJ
Apr. 20	BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024	Apr. 25	AQ
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024	Apr. 24	AQ
BioArctic and Eisai sign research evaluation agreement regarding BAN2802	Apr. 20	AQ
Notice of Annual General Meeting in BioArctic AB (publ)	Apr. 19	AQ
BioArctic publishes the Annual Report for 2023	Apr. 18	AQ
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB	Apr. 16	AQ
BioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm	Apr. 10	AQ
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed	Mar. 31	AQ
BioArctic AB - Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	Mar. 25	AQ
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	Mar. 22	AQ
Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease	Mar. 19	AQ
New data on lecanemab presented at the 2024 AD/PD™ congress	Mar. 11	AQ
BioArctic's partner Eisai presents updated sales simulation for Leqembi at its annual press conference	Mar. 08	AQ
BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference	Mar. 07	AQ
BioArctic AB - Latest data on lecanemab to be presented at the 2024 AD/PD congress	Mar. 01	AQ
Number of shares and votes in BioArctic AB (publ) as of February 29, 2024	Feb. 29	AQ
Latest data on lecanemab to be presented at the 2024 AD/PD™ congress	Feb. 29	AQ
BioArctic's CEO Gunilla Osswald Winner of The Arthur D. Little Nordic Life Science Award	Feb. 22	AQ
Interim Report for the period October - December 2023	Feb. 14	AQ
Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023	Feb. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioArctic AB

Equities

BIOA B

SE0010323311

Press Releases

Filters